L
Lario Therapeutics
Precision medicines for severe neurological disorders
About Lario Therapeutics
Lario Therapeutics is a biopharmaceutical company developing first-in-class, disease-modifying precision medicines for severe neurological disorders, with a focus on genetically validated targets. The company was founded in 2021 by CEO Dr. Henning Steinhagen and Head of Project Management Daniel Gill. It was established as a spin-out from Epidarex Exeed, the therapeutic discovery engine of Epidarex Capital, with initial seed investment from Epidarex Capital and Axxam.
Lario Therapeutics' primary mission is to create novel treatments for patients with conditions such as severe pediatric epilepsies, including CDKL5 Deficiency Disorder (CDD), and neurodegenerative disorders like Parkinson's disease. The company's therapeutic pipeline centers on modulating ion channels, such as their lead programs on CaV2.3 inhibitors. These orally active, CNS-penetrant compounds are being investigated for their potential as anti-seizure therapeutics and as a disease-modifying approach for Parkinson's. The company's approach is based on the discovery that CaV2.3 is a key target for the CDKL5 protein, which is deregulated in CDD, a prevalent form of genetic Developmental and Epileptic Encephalopathy (DEE).
The company's business model involves advancing its pipeline of genetically validated programs through preclinical development towards Investigational New Drug (IND) applications and clinical trials. Lario Therapeutics has secured significant funding to support its research, including a $6 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) in July 2024 to support its preclinical research on CaV2.3 calcium channel inhibitors. This grant also supports a collaboration with the Oxford Parkinson's Disease Centre. In November 2023, the company received the “Company Making a Difference Award” from the Loulou Foundation at the CDKL5 Forum, recognizing its commitment to preclinical therapeutic development for CDD.
Source: Dealroom company dataNews
Open roles
Lario Therapeutics in the Edinburgh ecosystem
The Lario Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lario Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lario Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

